Axsome Therapeutics Announces Proposed Public Offering of Common Stock
March 20, 2017 16:06 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
March 07, 2017 16:35 ET
|
Axsome Therapeutics, Inc.
Interim analysis results from two Phase 3 trials of AXS-02 in separate indications anticipated in 2H 2017 Top-line results from the Phase 3 STRIDE-1 trial of AXS-05 in treatment resistant depression...
Axsome Therapeutics to Present at the 29th Annual ROTH Conference
February 27, 2017 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression
February 14, 2017 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference
February 13, 2017 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the 2017 BIO CEO & Investor Conference
February 07, 2017 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at Biotech Showcase 2017
January 04, 2017 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
January 03, 2017 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley Bank
November 10, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at Upcoming Investor Conferences
September 06, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...